American Psychiatric Association practice guideline for the treatment of patients with Borderline Personality Disorder.

Format:

Book

Author/Creator:

American Psychiatric Association.

Language:

English

Subjects (All):

Borderline Personality Disorder--therapy.

Psychotherapy--methods.

Medical Subjects:

Borderline Personality Disorder--therapy.

Psychotherapy--methods.

Physical Description:

1 online resource (92 pages)

Edition:

2nd edition.

Place of Publication:

Washington, D.C.: American Psychiatric Association Publishing, 2024.

Summary:

Borderline personality disorder (BPD) is estimated to have a lifetime prevalence in the United States of approximately 1.4%–2.7%. It is characterized by a long-term pattern of instability in interpersonal relationships, unstable self-image, marked impulsivity, and/or affective instability. In addition, features can be evidenced by efforts to avoid real or feared abandonment, chronic feelings of emptiness, mood reactivity, recurrent self-injurious or suicidal behavior, other impulsive behaviors with potential for self-damaging effects, intense anger or difficulty with anger control, and transient paranoid ideation or stress-related dissociative symptoms. Although these manifestations can be quite heterogeneous, the lived experience of BPD can be associated with significant emotional pain and a diminished quality of life. Many individuals with BPD have co-occurring psychiatric or somatic conditions, and all-cause mortality is increased among those with BPD. Furthermore, the lifetime burden and psychosocial impairment associated with BPD can be substantial because it typically has an early onset and can persist for many years. These significant consequences support the need for early identification of BPD. Importantly, in contrast to many earlier views on BPD, treatment is effective, and symptoms can be reduced and managed. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Borderline Personality Disorder reviews current evidence and provides evidence-based statements that are intended to optimize the treatment of BPD. The guideline focuses on evidence-based treatments and includes additional information on assessment and treatment planning, which are an integral part of patient-centered care. It describes approaches to implementing recommendations and suggestions in clinical practice. By providing up-to-date knowledge, the guideline aims to help clinicians feel more confident in their skills for treating patients with BPD, thereby improving the care and well-being of their patients.

Contents:

Contents

Acronyms/Abbreviations

Introduction

Rationale

Scope of Document

Scope Constraints Related to the Systematic Review of Evidence

Scope Constraints Related to the Alternative DSM-5 Model for Personality Disorders

Overview of the Development Process

Rating the Strengths of Guideline Statements and Supporting Research Evidence

Proper Use of Guidelines

Guideline Statement Summary

Assessment and Determination of Treatment Plan

Psychosocial Interventions

Pharmacotherapy

Guideline Statements and Implementation

Statement 1 - Initial Assessment

Statement 2 - Quantitative Measures

Statement 3 - Treatment Planning

Statement 4 - Discussion of Diagnosis and Treatment

Statement 5 - Psychotherapy

Statement 6 - Clinical Review Before Medication Initiation

Statement 7 - Pharmacotherapy Principles

Statement 8 - Pharmacotherapy Review

Areas for Further Research

Methodological Issues

Research Topics

Prevention, Screening, and Assessment

Treatment Planning

Ethical Issues in BPD Assessment and Treatment

Guideline Development Process

Management of Potential Conflicts of Interest

Guideline Writing Group Composition

Systematic Review Methodology

Rating the Strength of Supporting Research Evidence

Rating the Strength of Guideline Statements

Use of Guidelines to Enhance Quality of Care

External Review

Funding and Approval

References

Disclosures

Individuals and Organizations That Submitted Comments

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.

ISBN:

0-89042-800-X

9780890428009

0-89042-710-0

9780890427101

OCLC:

1482678678